Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endovalve makes progress with percutaneous valve replacement:

This article was originally published in Clinica

Executive Summary

Endovalve has met some early milestones regarding the development of its percutaneous valve replacement system for treating mitral regurgitation. It has developed a to-scale functional model of the valve and anchor design, and has successfully demonstrated such feasibility criteria as foldability and deployment of the nitinol and stainless steel device, said the Princeton, New Jersey company. Bench testing on ex vivo sheep hearts has shown that when the valve device drops from the left atrium into the native mitral valve, it pushes away the native leaflets and is seated in place. The product's valve claws have also been shown to be able to "anchor" themselves onto the native annulus. Endovalve is now working on refining and optimising the valve's functionality, with a view to implanting the device in a live animal model.

You may also be interested in...

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.

Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts